Ekkio Capital strengthens its position in the shaping
orthopaedic implants with the acquisition of Watershed on behalf of SpiTrex
Ekkio Capital, with its strong expertise in the healthcare sector, is supporting the development of SPITREX. With the acquisition in California of Watershed, a specialist in 3D-printed orthopaedic implants, the aim is to offer the best solutions and technologies on the American and European markets and to quickly break through the $100 million barrier.
SpiTrex, formerly Mediliant, has established itself in 10 years as a leader in the production of orthopaedic implants in the Spine Extremity and Trauma ("SET") segment, with a "full service" offering on 2 continents, from design to management of the regulatory framework (US and European), including machining and sterile packaging.
As part of the transition, Watershed becomes SpiTrex 3D and brings 3D printing to a group with over 20 years' experience in the design and development of medical devices, particularly in the spine, trauma and extremity markets.
Watershed has an excellent reputation for additive manufacturing production and consultancy and frequently assists the FDA on these matters.
About Ekkio Capital
Ekkio Capital is an independent management company that has been investing for 20 years in growing European SMEs in four areas: Tourism & Leisure, Health, Security & Control, Eco-Responsibility. Ekkio Capital has developed a differentiating investment strategy, based on genuine sectoral and operational expertise to develop the business of SMEs, create value and position them as benchmark players in their sector. Ekkio Capital has made more than thirty investments and supported its holdings in the implementation of more than one hundred external growth projects. www.ekkio.com
